Latest Commercialisation News

EVE Health Group has announced a $1.3 million capital raising through a placement of shares and free attaching options, aimed at advancing its pharmaceutical product rollout and development pipeline. Several components of the offer await shareholder approval at an upcoming general meeting.

AdAlta Limited has been granted a key Canadian patent for its anti-fibrotic drug AD-214, completing its composition of matter protection across all major commercial markets. This milestone strengthens the company’s intellectual property portfolio and underpins its commercial strategy for AD-214.

Memphasys Limited confirms uninterrupted operations across the Middle East and North Africa, securing new orders and advancing regulatory approvals despite ongoing regional tensions.

CLINUVEL Pharmaceuticals reports record first-half profits and confirms CEO Philippe Wolgen’s leadership through a pivotal growth phase, prioritising its vitiligo program and Nasdaq ambitions.

Recce Pharmaceuticals is progressing its Phase 3 clinical trial of RECCE 327, a novel synthetic antibiotic targeting multidrug-resistant infections, with interim data from Indonesia supporting registration plans across ASEAN by 2026.

TMK Energy has raised $6 million in a heavily oversubscribed placement led by coal seam gas experts, aiming to accelerate drilling and commercialisation at its Gurvantes XXXV project.

Finder Energy has confirmed the technical feasibility of repurposing the Petrojarl I FPSO vessel for its Kuda Tasi and Jahal oil fields, setting the stage for a final investment decision by mid-2026.

Imricor Medical Systems has filed a Form 10 registration with the U.S. SEC, marking its transition to a U.S. reporting company amid ongoing FDA clearances and clinical trials. This move signals a significant step in its early commercialisation of MRI-guided cardiac ablation technology.

Hazer Group has inked a non-binding graphite offtake agreement with Green Steel of WA, marking a significant step in supplying low-emission steel production with up to 85,000 tonnes over 10 years.

EBR Systems marked a pivotal transition in 2025 with FDA approval of its WiSE CRT System and the initiation of U.S. commercial implants, generating $1.6 million in revenue. Despite this progress, the company reported a net loss of $48.8 million and completed a significant capital raise to support ongoing growth.

OMG Group has appointed Food & Dairy Co as the first official distributor of its new matcha brands, opening access to over 2,000 cafes and restaurants in NSW and Queensland. This move marks a key step in OMG’s strategy to expand its health-focused beverage portfolio.

EVE Health Group has increased its placement funding to $1.3 million, backed by a cornerstone investor with pharmaceutical expertise, advancing its reformulated drug programs targeting billion-dollar global markets.